1. Home
  2. FOUR vs BEAM Comparison

FOUR vs BEAM Comparison

Compare FOUR & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shift4 Payments Inc.

FOUR

Shift4 Payments Inc.

HOLD

Current Price

$39.16

Market Cap

3.2B

ML Signal

HOLD

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

SELL

Current Price

$23.29

Market Cap

2.6B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
FOUR
BEAM
Founded
1999
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2B
2.6B
IPO Year
2020
2019

Fundamental Metrics

Financial Performance
Metric
FOUR
BEAM
Price
$39.16
$23.29
Analyst Decision
Buy
Strong Buy
Analyst Count
25
15
Target Price
★ $52.86
$52.15
AVG Volume (30 Days)
1.7M
★ 1.7M
Earning Date
11-05-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 82.31
EPS
★ N/A
N/A
Revenue
★ $4,180,000,000.00
$24,000.00
Revenue This Year
$22.40
N/A
Revenue Next Year
$13.37
$29.19
P/E Ratio
$27.53
★ N/A
Revenue Growth
25.50
★ 33.33
52 Week Low
$34.56
$20.23
52 Week High
$77.50
$38.26

Technical Indicators

Market Signals
Indicator
FOUR
BEAM
Relative Strength Index (RSI) 45.88 40.52
Support Level $34.92 $22.49
Resistance Level $51.46 $26.72
Average True Range (ATR) 1.63 1.17
MACD 0.40 0.01
Stochastic Oscillator 65.23 4.89

Price Performance

Historical Comparison
FOUR
BEAM

About FOUR Shift4 Payments Inc.

Shift4 Payments Inc is an independent provider of software and payment processing solutions in the U.S., expanding internationally. Its payments platform offers integrated products and services across in-store, online, mobile and tablet-based channels, including end-to-end payment processing, merchant acquiring services, a proprietary omni-channel gateway, eCommerce capabilities, and reporting tools. The company distributes its services through internal sales teams and partners, including independent software vendors (ISVs) and value-added resellers (VARs). Revenue is predominantly recurring, derived mainly from processing fees and subscription revenue from POS software, business intelligence tools and other technology solutions. The company derives maximum revenue from the United States.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

Share on Social Networks: